Alimera Sciences, Inc. (ALIM)

NASDAQ: ALIM · IEX Real-Time Price · USD
5.08
-0.19 (-3.61%)
At close: Sep 29, 2022 4:00 PM
5.25
+0.17 (3.35%)
After-hours: Sep 29, 2022 4:00 PM EDT
-3.61%
Market Cap 35.54M
Revenue (ttm) 52.61M
Net Income (ttm) -17.36M
Shares Out 7.00M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE 65.79
Dividend n/a
Ex-Dividend Date n/a
Volume 4,025
Open 5.15
Previous Close 5.27
Day's Range 5.15 - 5.25
52-Week Range 3.94 - 7.92
Beta 1.32
Analysts Buy
Price Target 12.92 (+154.3%)
Earnings Date Oct 26, 2022

About ALIM

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies,... [Read more...]

Industry Pharmaceuticals
IPO Date Apr 22, 2010
CEO Richard Eiswirth
Employees 145
Stock Exchange NASDAQ
Ticker Symbol ALIM
Full Company Profile

Financial Performance

In 2021, ALIM's revenue was $59.03 million, an increase of 16.15% compared to the previous year's $50.82 million. Losses were -$4.37 million, -18.11% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ALIM stock is "Buy." The 12-month stock price forecast is 12.92, which is an increase of 154.33% from the latest price.

Price Target
$12.92
(154.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network

ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy ILUVIEN or faricimab (6.0 mg) injections versus observat...

1 week ago - GlobeNewsWire

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland

Reimbursement granted with no restrictions to the label Reimbursement granted with no restrictions to the label

1 week ago - GlobeNewsWire

Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?

Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

1 week ago - Zacks Investment Research

Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

Positive findings from the RIVER study and data on retreatment with ILUVIEN available Positive findings from the RIVER study and data on retreatment with ILUVIEN available

1 month ago - GlobeNewsWire

Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors

Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks ...

1 month ago - Zacks Investment Research

Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why

Alimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it throu...

1 month ago - Zacks Investment Research

Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?

Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conce...

1 month ago - GlobeNewsWire

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Reimbursement granted with no restrictions to the label Alimera to begin selling later in Q3

1 month ago - GlobeNewsWire

Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM)

Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks ...

1 month ago - Zacks Investment Research

Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year?

Here is how Alimera Sciences (ALIM) and Eli Lilly (LLY) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Alimera Sciences Announces Second Quarter 2022 Financial Results

ATLANTA, July 27, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription opht...

2 months ago - GlobeNewsWire

Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate U...

Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time

2 months ago - GlobeNewsWire

Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France

Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3 Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the p...

2 months ago - GlobeNewsWire

Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress

ILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists (ASRS) conference. ILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists (AS...

2 months ago - GlobeNewsWire

Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow ILUVIEN receives approval and pricing for non-infectious uveitis aff...

2 months ago - GlobeNewsWire

Phase III Clinical Study IND Accepted in China for Alimera's Fluocinolone Acetonide Intravitreal Implant

ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners conc...

3 months ago - GlobeNewsWire

Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes

Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choice Recently presented data further demonstrate steroid challenge is ...

4 months ago - GlobeNewsWire

Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Alimera Sciences Reports First Quarter 2022 Results

ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerne...

4 months ago - GlobeNewsWire

Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update

Conference Call to be held the same day at 9:00am Eastern Time Conference Call to be held the same day at 9:00am Eastern Time

4 months ago - GlobeNewsWire

Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress

Follow up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research in Vision and Ophthalmology (ARVO) conference Follow up ILUVIEN® PALADIN data to be presented onsite at the ...

5 months ago - GlobeNewsWire

New Strong Sell Stocks for April 26th

ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022

Other symbols: ADAPANIK
5 months ago - Zacks Investment Research

Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocation

ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners con...

5 months ago - GlobeNewsWire